Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

ASH 2017 and Car T View overview page

0:50
Are there promising treatment options for multiple myeloma on the horizon?
Irene Ghobrial • 10 Dec 2017
1:12
Novel ALL treatment strategies: CAR T-cells
Elias Jabbour • 10 Dec 2017
1:53
CAR T-cells for CLL: ibrutinib pre-treatment, T-cell quality and future predictions
Constantine Tam • 9 Dec 2017
2:25
Update on immunotherapy trials for AML from ASH 2017: bispecific DARTs, CAR T-cells and ADCs
Marina Konopleva • 9 Dec 2017
2:00
ZUMA-1 trial: FDA approval and follow-up of CAR T-cell product axicabtagene ciloleucel
Yi Lin • 9 Dec 2017
2:38
Prophylactic treatment for CAR T-cell toxicity shows promising results
Yi Lin • 9 Dec 2017
1:46
Next-generation CAR T-cell products for 2018
Yi Lin • 9 Dec 2017
3:17
Anti-BCMA CAR T-cells for MM: durable clinical responses with bb2121
Yi Lin • 9 Dec 2017
3:38
Finding the expansion balance: CAR T-cell response markers identified from the trial of JCAR017
Tanya Siddiqi • 9 Dec 2017
3:07
Follow-up CAR T-cell data so far
Tanya Siddiqi • 9 Dec 2017
1:11
Safety profile of anti-CD19 CAR T-cell therapy axicabtagene ciloleucel
Sattva Neelapu • 9 Dec 2017
1:41
New CAR T-cell targeting SLAMF7 shows efficacy against multiple myeloma
Sattva Neelapu • 9 Dec 2017
1:21
Anti-CD22 CAR T-cell therapy for ALL: trial update, utility for salvage and CD19 status
Nirali Shah • 9 Dec 2017
0:46
Bispecific CAR T-cell therapy: combining anti-CD19 and CD22 CAR T-cells
Nirali Shah • 9 Dec 2017
1:19
Cytokine storms: CAR T-cell hyperinflammatory response distinct from cytokine release syndrome?
Nirali Shah • 9 Dec 2017
1:29
Take-home message on CAR T-cell therapy for lymphoma from ASH 2017
Jeremy Abramson • 9 Dec 2017
The content of VJHemOnc is intended for healthcare professionals